Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure Acorda Therapeutics, Inc. today announced that the 1st patient has been enrolled in the first medical trial of Glial Development Aspect 2 . Acorda is collaborating with the Vanderbilt University Center and Vascular Institute to carry out this Phase 1 single-dosage trial in individuals with heart failure. In preclinical models, GGF2 restored the integrity of center muscle mass and improved function, which symbolizes a novel method of treat heart failing, said Anthony Caggiano, M.D. Ph.D., Vice President of Research and Development at Acorda.The present research shows for the very first time a immediate protective effect of SHH pathway against AMI on cardiac cells. Altogether these pleiotropic ramifications of SHH participate in cardioprotection by performing concurrently on different targets.
Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom, M.D., Jonas Oldgren, M.D., Ph.D., Amit Parekh, M.D., Janice Pogue, M.Sc., Paul A. Reilly, Ph.D., Ellison Themeles, B.A., Jeanne Varrone, M.D., Susan Wang, Ph.D., Marco Alings, M.D., Ph.D., Denis Xavier, M.D., Jun Zhu, M.D., Rafael Diaz, M.D., Basil S.